$194.00 - 1 mg

$679.00 - 5 mg

All prices in Australian dollars

Molecular Formula
Molecular Weight
>95% by HPLC
Long Term Storage
Soluble in ethanol, methanol, DMF or DMSO.

Download Data Sheets

Application Notes

Viridicatol is a polar metabolite first isolated from Penicillium cyclopium and P. viridicatum by Birkinshaw and collaborators in 1963. Viridicatol is a 2,3-dihydroxyquinoline which, like its analogue viridicatin, exists in equilibrium with its keto-tautomer. Viridicatol acts as an anti-inflammatory agent by suppressing the expression of pro-inflammatory mediators such as inducible nitric oxide synthase (iNOS) and cyclooxygenase (COX)-2, via inhibition of the nuclear factor-kappa B (NF-κB) pathway in LPS stimulated cells. Further, viridicatol is a selective inhibitor of PTP1B, a potential drug target for the treatment of type 2 diabetes and obesity.


  • Studies in the biochemistry of micro-organisms. 114. Viridicatol and cyclopenol, metabolites of Penicillium viridicatum Westling and Penicillium cyclopium Westling. Birkinshaw J.H. et al., Biochem J. 1963, 89, 196.
  • Production of secondary metabolites by some terverticillate penicillia on carbohydrate-rich and meat substrates. Nunez. F. et al., J. Food Protect. 2007, 70, 2829.
  • PTP1B inhibitory secondary metabolites from marine-derived fungal strains Penicillium spp. and Eurotium sp. Sohn J.H. et al., J. Microbiol. Biotech. 2013, 23, 1206.

Other Products